Immunocore (NASDAQ:IMCR) Earns "Equal Weight" Rating from Morgan Stanley

Immunocore (NASDAQ:IMCR - Get Free Report)'s stock had its "equal weight" rating restated by Morgan Stanley in a report issued on Friday, MarketBeat reports. They currently have a $35.00 price objective on the stock. Morgan Stanley's price objective would suggest a potential upside of 23.15% from the company's previous close.

Other research analysts also recently issued reports about the stock. HC Wainwright reissued a "buy" rating and issued a $100.00 target price on shares of Immunocore in a research report on Friday, February 28th. Needham & Company LLC reiterated a "buy" rating and set a $71.00 price objective on shares of Immunocore in a research report on Thursday, February 27th. Finally, Mizuho downgraded shares of Immunocore from an "outperform" rating to a "neutral" rating and cut their target price for the company from $72.00 to $38.00 in a research note on Monday, November 11th. One analyst has rated the stock with a sell rating, four have given a hold rating and eight have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $65.64.

Immunocore Trading Down 2.0 %

IMCR traded down $0.58 during trading on Friday, reaching $28.42. The company had a trading volume of 503,359 shares, compared to its average volume of 433,150. The firm's 50-day simple moving average is $30.14 and its 200 day simple moving average is $31.47. The company has a debt-to-equity ratio of 1.03, a quick ratio of 3.76 and a current ratio of 3.78. The company has a market cap of $1.42 billion, a price-to-earnings ratio of -29.92 and a beta of 0.79. Immunocore has a 12-month low of $27.23 and a 12-month high of $66.00.

Remove Ads

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Wellington Management Group LLP grew its stake in shares of Immunocore by 10.5% in the 3rd quarter. Wellington Management Group LLP now owns 7,048,833 shares of the company's stock valued at $219,430,000 after buying an additional 668,382 shares in the last quarter. Groupama Asset Managment acquired a new stake in Immunocore in the fourth quarter valued at approximately $17,700,000. Primecap Management Co. CA grew its position in Immunocore by 26.7% in the third quarter. Primecap Management Co. CA now owns 2,472,020 shares of the company's stock worth $76,954,000 after acquiring an additional 520,950 shares in the last quarter. Deep Track Capital LP acquired a new position in shares of Immunocore during the 4th quarter worth $15,322,000. Finally, Tang Capital Management LLC raised its holdings in shares of Immunocore by 40.7% during the 4th quarter. Tang Capital Management LLC now owns 1,555,600 shares of the company's stock valued at $45,890,000 after purchasing an additional 450,000 shares in the last quarter. 84.50% of the stock is owned by institutional investors and hedge funds.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.